Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Near ZIP Code:  within 100 miles of 78229
Results 1-25 of 138 for your search:
Start Over
Image-Guided Radiosurgery or Stereotactic Body Radiation Therapy in Treating Patients with Localized Spine Metastasis
Status: Active
Phase: Phase III, Phase II
Type: Treatment
Age: 18 and over
Trial IDs: RTOG 0631, NCI-2009-01687, CDR0000646803, NCT00922974
Chemotherapy Alone or Chemotherapy Plus Radiation Therapy in Treating Patients with Locally Advanced Rectal Cancer Undergoing Surgery
Status: Active
Phase: Phase III, Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: N1048, NCI-2012-00234, CDR0000715321, NCCTG-N1048, PN1048_A11PAMDREVW01, NCT01515787
Temozolomide with or without Veliparib in Treating Patients with Newly Diagnosed Glioblastoma Multiforme
Status: Active
Phase: Phase III, Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: A071102, NCI-2014-00616, CALGB-A071102, NCT02152982
Lung-MAP: Biomarker-Targeted Second-Line Therapy in Treating Patients with Recurrent Stage IV Squamous Cell Lung Cancer
Status: Active
Phase: Phase III, Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: S1400, NCI-2014-00627, S1400E, S1400A, S1400I, S1400C, S1400D, S1400B, NCT02154490
Radiation Therapy with or without Combination Chemotherapy or Pazopanib Hydrochloride before Surgery in Treating Patients with Newly Diagnosed Non-Rhabdomyosarcoma Soft Tissue Sarcomas That Can Be Removed by Surgery
Status: Active
Phase: Phase III, Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 2 and over
Trial IDs: ARST1321, NCI-2014-01340, NCT02180867
Afatinib Dimaleate with or without Cetuximab in Treating Patients with Newly Diagnosed Stage IV or Recurrent, EGFR Mutation Positive Non-small Cell Lung Cancer
Status: Active
Phase: Phase III, Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: Not specified
Trial IDs: S1403, NCI-2014-02405, BI 1200.124, NCT02438722
Chemotherapy and Radiation Therapy in Treating Young Patients with Newly Diagnosed, Previously Untreated, High-Risk Medulloblastoma
Status: Active
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Age: 3 to 21
Trial IDs: ACNS0332, NCI-2009-00336, COG-ACNS0332, CDR0000511991, NCT00392327
Radiation Therapy with or without Cetuximab in Treating Patients Who Have Undergone Surgery for Locally Advanced Head and Neck Cancer
Status: Active
Phase: Phase III
Type: Supportive care, Treatment
Age: 18 and over
Trial IDs: RTOG-0920, NCI-2011-00878, CDR0000651536, NCT01311063, NCT00956007
Risk-Based Therapy in Treating Younger Patients with Newly Diagnosed Liver Cancer
Status: Active
Phase: Phase III
Type: Tissue collection/Repository, Treatment
Age: 21 and under
Trial IDs: AHEP0731, NCI-2011-01975, CDR0000654889, NCT02265692, COG-AHEP0731, NCT00980460
Maintenance Chemotherapy or Observation Following Induction Chemotherapy and Radiation Therapy in Treating Younger Patients With Newly Diagnosed Ependymoma
Status: Active
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Age: 1 to 21
Trial IDs: ACNS0831, NCI-2011-02029, COG-ACNS0831, CDR0000668560, NCT01096368
Radiation Therapy With or Without Chemotherapy in Patients With Stage I or Stage II Cervical Cancer Who Previously Underwent Surgery
Status: Active
Phase: Phase III
Type: Tissue collection/Repository, Treatment
Age: 18 and over
Trial IDs: GOG-0263, NCI-2011-02037, CDR0000670125, NCT01101451
Risk-Adapted Chemotherapy in Treating Younger Patients with Newly Diagnosed Standard-Risk Acute Lymphoblastic Leukemia or Localized B-Lineage Lymphoblastic Lymphoma
Status: Active
Phase: Phase III
Type: Supportive care, Treatment
Age: 1 to < 10
Trial IDs: AALL0932, NCI-2011-02599, CDR0000683227, COG-AALL0932, NCT01190930
Standard or Extended Pelvic Lymphadenectomy in Treating Patients Undergoing Surgery for Invasive Bladder Cancer
Status: Active
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: S1011, NCI-2011-02604, CDR0000686574, SWOG-S1011, NCT01224665
Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane with or without Chemotherapy in Treating Patients with Invasive RxPONDER Breast Cancer
Status: Active
Phase: Phase III
Type: Health services research, Treatment
Age: 18 and over
Trial IDs: S1007, NCI-2011-02623, CDR0000692475, PS1007_A11PAMDREVW01, SWOG-S1007, NCT01272037
Caspofungin Acetate or Fluconazole in Preventing Invasive Fungal Infections in Patients with Acute Myeloid Leukemia Who Are Undergoing Chemotherapy
Status: Active
Phase: Phase III
Type: Biomarker/Laboratory analysis, Supportive care
Age: 3 months to 30 years
Trial IDs: ACCL0933, NCI-2011-02640, CDR0000695748, COG-ACCL0933, NCT01307579
Eflornithine and/or Sulindac in Preventing Recurrence of High-Risk Adenomas and Second Primary Disease in Patients with Stage 0-III Colon or Rectal Cancer
Status: Active
Phase: Phase III
Type: Prevention
Age: 18 and over
Trial IDs: S0820, NCI-2012-02067, SWOG-S0820, NCT01349881
Androgen-Deprivation Therapy and Radiation Therapy in Treating Patients with Prostate Cancer
Status: Active
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: RTOG 0924, NCI-2011-02674, CDR0000701128, PRTOG-0924_A03PAMDREVW01, NCT01368588
Bortezomib and Sorafenib Tosylate in Treating Patients with Newly Diagnosed Acute Myeloid Leukemia
Status: Active
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Age: Under 30
Trial IDs: AAML1031, NCI-2011-02670, COG-AAML1031, CDR0000701850, NCT01371981
Combination Chemotherapy in Treating Young Patients with Newly Diagnosed High-Risk B Acute Lymphoblastic Leukemia and Ph-Like TKI Sensitive Mutations
Status: Active
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Age: 1 to 30
Trial IDs: AALL1131, NCI-2011-03797, CDR0000706370, COG-AALL1131, NCT01406756
Cisplatin and Radiation Therapy with or without Carboplatin and Paclitaxel in Patients with Locally Advanced Cervical Cancer
Status: Active
Phase: Phase III
Type: Supportive care, Treatment
Age: 18 and over
Trial IDs: ANZGOG-0902-GOG-0274, NCI-2011-02978, ANZGOG-0902/GOG-0274/RTOG-1174, CDR0000706698, GOG-0274, RTOG-1174, ANZGOG-0902, NCT01414608
Standard or Accelerated Hypofractionated Image-Guided Radiation Therapy in Treating Patients With Stage II-III Non-small Cell Lung Cancer and Poor Performance Status
Status: Active
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: STU 052011-093, NCI-2013-00783, NCT01459497
Assessing Compliance with Mercaptopurine Treatment in Younger Patients with Acute Lymphoblastic Leukemia in First Remission
Status: Active
Phase: Phase III
Type: Behavioral study, Biomarker/Laboratory analysis, Educational/Counseling/Training
Age: 12 to 20
Trial IDs: ACCL1033, NCI-2012-00105, CDR0000721559, NCT01476852, COG-ACCL1033, NCT01503632
Hormone Therapy with or without Everolimus in Treating Patients with Breast Cancer
Status: Active
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: S1207, NCI-2012-01995, CDR0000738280, SWOG-S1207, S1207/NSABP B-53, NCT01674140
Armodafinil in Reducing Cancer-Related Fatigue in Patients with High-Grade Glioma
Status: Active
Phase: Phase III
Type: Supportive care
Age: 18 and over
Trial IDs: A221101, NCI-2012-02020, N10C3, NCT01781468
Start Over